<DOC>
	<DOCNO>NCT02171767</DOCNO>
	<brief_summary>Study ass pharmacokinetics incl . dose proportionality , safety tolerability 4 different dosage strength BIBW 2992 tablet ( final formulation 20 mg , 30 mg , 40 mg , 50 mg ) administer single dos healthy male volunteer</brief_summary>
	<brief_title>Safety Tolerability 4 Different Dosage Strengths BIBW 2992 Tablets Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male accord complete medical history , include physical examination , vital sign ( blood pressure , pulse rate ) , 12lead Electrocardiogram ( ECG ) , clinical laboratory test Age 21 55 year , inclusive Body mass index 18.5 29.9 kg/m2 , inclusive Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation Any finding medical examination ( include Blood Pressure ( BP ) , Puse Rate ( PR ) Electrocardiogram ( ECG ) ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include drug allergy excipients ) Intake drug long halflife ( &gt; 24 hour ) within 1 month prior administration trial drug trial Use drug ( include herbal preparation , vitamin nutrient supplement ) within 10 day prior administration trial drug trial Participation another trial investigational drug within 2 month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke within inhouse period 12 hour 25 hour administration trial drug Alcohol abuse ( 30 g/day ) Drug abuse Blood donation ( 100 mL within 4 week prior administration trial drug trial ) Excessive physical activity ( within 1 week prior administration trial drug trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) A history additional risk factor Torsades de Points , e.g. , heart failure , hypokalemia , family history Long QT Syndrome Exclusion criterion specific study : History clinically relevant skin disease , psoriasis moderate/severe acne History evidence interstitial lung disease Males unwilling use medically acceptable method contraception first 3 month administration trial drug . Acceptable method contraception use male volunteer include sexual abstinence , vasectomy perform least 1 year prior dosing , barrier contraception another medically accept contraceptive method</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>